Amicus
Amicus, officially known as Amicus Therapeutics, Inc., is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in the United States. Founded in 2002, the company has made significant strides in developing innovative therapies for rare and orphan diseases, particularly in the field of enzyme replacement therapies.
With a strong operational presence across North America and Europe, Amicus is renowned for its unique approach to drug development, focusing on precision medicine and patient-centric solutions. Their flagship products, including Galafold, exemplify their commitment to addressing unmet medical needs with cutting-edge technology.
Recognised for its robust pipeline and strategic partnerships, Amicus has established itself as a leader in the biopharmaceutical sector, continually striving to improve the lives of patients worldwide.
-19 vs industry average
Amicus’s score of 21 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Amicus?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2020
Reported emissions
Scope 3 accounts for ••• of total emissions.
Amicus's reported carbon emissions
Amicus, a pharmaceutical preparation manufacturer headquartered in the US, reported total emissions of approximately 302,400 kg CO2e for the year 2020. This figure represents their global emissions for that period. Specific breakdowns for Scope 1, Scope 2, and Scope 3 emissions for 2020 were not available.
Amicus's emissions data is not cascaded from a parent organisation. The company's disclosed reduction targets and commitments are not detailed in the provided information. Further details on Amicus's climate strategy and specific emissions performance in subsequent years would be required to assess their progress against any climate goals.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Amicus’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Amicus yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project